These clinical results are in line with the hypothesized drug’s mechanism of action, which is based on an improved intratumoral penetration of chemotherapeutic agents and increased tumor lymphocyte infiltration, due to NGR-hTNF activity on newly formed tumor vasculature. The gene discussed is RTN4R; the disease is neoplasm.